Volume 8, Number 2, Supplement 1 (March/April 2009)

Reviews

3

About This Continuing Education Activity

full text

160 kb

5

Best Practice Management of CINV in Oncology Patients:  I. Physiology and Treatment of CINV
Multiple Neurotransmitters and Receptors and the Need for Combination Therapeutic Approaches
David G. Frame, PharmD

Clnical Hematology/Oncology/BMT Specialist, University of Michigan, Ann Arbor

abstract

full text

382 kb

10

Best Practice Management of CINV in Oncology Patients:  II. Antiemetic Guidelines and Rationale for Use
Rita Wickham, PhD, RN, AOCN

Rush University College of Nursing, Chicago, Illinois

abstract

full text

173 kb

learning assessment and evaluation form

Conference Highlights

16

About This Continuing Education Activity

full text

395 kb

19

Key Supportive Care Studies from ASCO 2009
Barbara A. Murphy, MD, and Michael J. Fisch, MD, MPH

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, and General Medical Oncology Program, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

19

Managing Psychological Issues
Jimmie C. Holland, MD, William S. Breitbart, MD, and Susan D. Block, MD

Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York; Weill Medical College of Cornell University, Pain and Palliative Care Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York; and Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Harvard Medical School Center for Palliative Care, Boston, Massachusetts

21

Cancer and Nutrition
Carol Rees Parrish, MS, RD, Eduardo Bruera, MD, and Nancy J. Emenaker, PhD, MEd, RD

University of Virginia Health System, Charlottesville, Virginia; Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and Nutritional Science Research Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland

22

Peripheral Neurotoxicities
Gary J. Bennett, PhD, Axel Grothey, MD, and Charles L. Loprinzi, MD

Department of Anesthesia, Faculty of Dentistry and The Alan Edwards Centre for Research on Pain, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada; Division of Medical Oncology, Department of Oncology, Mayo Clinic, North Central Cancer Treatment Group, Rochester, Minnesota; and Mayo Clinic College of Medicine, Rochester, Minnesota

24

Cancer Pain Management
Steven D. Passik, PhD, Frank Porreca, PhD, and Judith A. Paice, RhD, RN, FAAN

Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, The Rockefeller University Hospital, New York; Departments of Pharmacology and Anesthesiology, Theme for Medical Neuroscience, The University of Artizona College of Medicine, Tucson, Arizona; and Division of Hematology-Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

25

Complementary and Alternative Medicine
Gary Deng, MD, PhD, Stephen M. Sagar, BSc(Hons), MB, BS, MRCP, FRCR, FRCPC, and Lorenzo Cohen, PhD

Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York; McMaster University, Ontario Cancer Treatment and Research Foundation, Hamilton Health Sciences Corporation, Juravinski Cancer Centre, Hamilton, Ontario, Canada; and Department of Behaviorial Science, Cancer Prevention and Population Sciences, Department of General Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

26

Enhancing Sexual Function and Preserving Fertility
Deborah Watkins Bruner, RN, PhD, FAAN, James A. Talcott, MD, SM, and Teresa K. Woodruff, PhD

Cancer Prevention and Control Program, Recruitment, Retention and Outreach Core Facility, Abramson Cancer Center, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania; Harvard University Medical School, Massachusetts General Hospital, Boston, Massashusetts; and Center for Reproductive Research, Department of Neurobiology and Physiology, Department of Medicine, Institute for Women’s Health Research, Feinberg School of Medicine at Northwestern University, Evanston, Illinois

27

Improving Palliative Care at a Global Level
Kathleen M. Foley, MD

Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center, Neuroscience and Clinical Pharmacology, Weill Medical College of Cornell University, New York

28

Communicating with Cancer Patients
Paul Glare, MD, Paula Rauch, MD, and Lynne H. Nguyen, MPH

Pain and Palliative Care Service, Memorial Sloan-Kettering Cacer Center, Memorial Hospital for Cancer and Allied Diseases, Department of Medicine, New York; Harvard Medical School, Child Psychiatry Consultation Service, Massachusetts General Hospital, Boston, Massachusetts; and Minority and Women Clinical Trials Recruitment Program, Department of Heath Disparities Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

30

Palliation of Advanced Disease
Theodore Lawrence, MD, PhD, David S. K. Lu, MD, and Gregory J. Riely, MD, PhD

Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, Michigan; Cross-Section Interventional Radiology, Computed Tomography, HIFU and Tumor Ablation Program, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; and Thoracic Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

31

Managing Gastrointestinal Side Effects of Cancer Treatment
Stephen Sonis, DMD, DMSc, Paul J. Hesketh, MD, and Joanna M. Brell, MD

Oral Medicine and Oral Pathology, Harvard School of Dental Medicine, Division of Oral Medicine, Oral and Maxillofacial Surgery and Dentistry, Dana-Farber Cancer Institute, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Hematology and Oncology, Caritas St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Massachusetts; Symptom Management and Drug Development, Community Oncology and Prevention Trials Research Group, National Cancer Institute, Rockville, Maryland

32

Pharmacologic Complications:  When Good Drugs Do Harm
Mario E. Lacouture, MD, Jean-Bernard Durand, MD, FACP, FCCP, FACC, and Lee Schwartzberg, MD, FACP

Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York; Cardiomyopathy Services, Cardiovascular Genetics Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and University of Tennessee, The West Clinic, Hematology and Medical Oncology, Myelosuppression Unit, Baptist Memphis Hospital, Memphis, Tennessee

© 2010 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.